lifethreaten
infect
occur
frequent
patient
chronic
diseas
increas
approxim
per
year
larg
cohort
studi
n
found
patient
sever
sepsi
least
one
chronic
comorbid
complic
diabet
mellitu
dm
present
chronic
obstruct
pulmonari
diseas
copd
chronic
kidney
diseas
ckd
chronic
liver
diseas
although
patient
condit
primari
defect
immun
system
often
variou
immun
abnorm
make
prone
specif
infect
review
describ
lifethreaten
infect
occur
patient
chronic
medic
diseas
name
dm
copd
ckd
cirrhosi
heart
failur
hf
discuss
manag
report
outcom
variou
chang
innat
cellmed
humor
immun
describ
patient
chronic
medic
condit
reduc
neutrophil
chemotaxi
stimul
blunt
inflammatori
respons
endotoxemia
shown
dm
function
abnorm
neutrophil
monocyt
dendrit
cell
lymphocyt
uremia
cirrhosi
sever
abnorm
describ
includ
reduc
number
function
kupffer
cell
impair
phagocytot
function
neutrophil
downregul
proinflammatori
cytokin
product
lipopolysaccharid
stimul
patient
hf
natur
killer
cell
shown
decreas
sensit
activ
interleukin
il
interferong
addit
soft
tissu
breakag
dm
edema
cirrhosi
hf
increas
risk
skin
soft
tissu
infect
ssti
glucosuria
promot
bacteri
growth
urinari
tract
presenc
hemodialyi
periton
dialysi
access
may
lead
bacteri
invas
blood
periton
space
injuri
respiratori
epitheli
cell
ciliari
dysfunct
corticosteroid
therapi
predispos
patient
copd
recurr
respiratori
tract
infect
cirrhosi
transloc
bacteria
ascit
fluid
lead
spontan
bacteri
periton
sbp
presenc
intrahepat
shunt
predispos
endotips
dm
global
health
problem
preval
dm
among
adult
worldwid
unit
state
canada
preval
gener
lower
europ
higher
middl
east
worldwid
dm
preval
expect
increas
studi
intens
care
unit
icu
consist
shown
higher
dm
preval
populationbas
studi
suggest
dm
predispos
critic
ill
dm
preval
among
critic
ill
patient
unit
state
univers
health
system
consortium
cohort
mayo
cohort
howev
less
preval
european
cohort
critic
ill
patient
sepsi
dm
associ
increas
risk
specif
infect
prospect
dutch
cohort
studi
compar
diabet
patient
hypertens
nondiabet
patient
dm
associ
increas
risk
urinari
tract
infect
uti
ssti
lower
respiratori
tract
infect
uti
uti
among
common
infect
affect
diabet
patient
often
complic
emphysemat
cystiti
rare
seriou
complic
lower
uti
occur
mainli
individu
dm
commonli
occur
due
escherichia
coli
pathogen
includ
enterobact
proteu
klebsiella
candida
speci
also
implic
emphysemat
pyelonephr
almost
exclus
occur
patient
diabet
result
sever
form
acut
multifoc
bacteri
nephriti
e
coli
commonli
implic
pathogen
follow
enter
gramneg
bacilli
ssti
longitudin
prospect
outpati
studi
show
diabet
patient
develop
foot
infect
ssti
compos
heterogen
condit
includ
simpl
cellul
infect
foot
ulcer
without
cellul
necrot
fasciiti
deep
abscess
osteomyel
septic
arthriti
caus
pathogen
vari
depend
condit
among
pathogen
bhemolyt
streptococci
staphylococcu
aureu
predomin
cellul
acut
infect
foot
ulcer
methicillinresist
aureu
mrsa
preval
increas
infect
foot
ulcer
multicent
studi
hospit
diabet
patient
ssti
posit
cultur
show
mrsa
isol
significantli
increas
preval
studi
india
also
show
increas
preval
multidrugresist
gramneg
organ
gramneg
bacteria
anaerob
consid
chronic
deeper
infect
polymicrobi
infect
consid
sever
situat
fournier
gangren
repres
sever
form
ssti
involv
perin
perian
genit
region
patient
dm
infect
microorgan
usual
mix
aerob
anaerob
bacteria
dm
also
risk
factor
fungal
infect
includ
candidiasi
mucormycosi
populationbas
surveil
candidemia
found
among
diabet
adult
averag
annual
incid
candidemia
per
popul
approxim
rhinocerebr
mucormycosi
case
occur
patient
dm
infect
dm
also
increas
morbid
associ
certain
viral
infect
dm
associ
increas
hospit
icu
admiss
infect
icu
dm
found
predictor
central
lineassoci
bloodstream
infect
caus
gramneg
bacteria
earli
appropri
antimicrobi
therapi
shown
associ
lower
mortal
patient
sever
sepsi
septic
shock
dm
consid
risk
factor
infect
resist
microorgan
henc
empir
therapi
broad
direct
suspect
caus
agent
take
consider
local
suscept
pattern
current
evid
suggest
treatment
choic
emphysemat
pyelonephr
medic
manag
combin
percutan
drainag
howev
nephrectomi
may
need
patient
extens
diffus
ga
renal
destruct
debrid
amput
may
necessari
diabet
foot
ulcer
deep
infect
gangren
necrot
fasciiti
fournier
gangren
frequent
requir
surgic
intervent
immedi
debrid
necrot
tissu
one
principl
treatment
import
improv
surviv
mucormycosi
aggress
surgeri
longterm
therapi
amphotericin
b
may
lead
improv
outcom
insulin
therapi
essenti
manag
infect
diabet
patient
hyperglycemia
metaanalysi
random
control
trial
total
critic
ill
adult
patient
found
tight
glucos
control
diabet
nondiabet
patient
medic
immunocompromis
patient
associ
significantli
decreas
risk
septicemia
howev
intens
insulin
therapi
shown
reduc
mortal
critic
ill
diabet
nondiabet
patient
agent
use
reduc
cardiovascular
risk
evalu
infect
diabet
patient
retrospect
casecontrol
studi
diabet
patient
van
de
gard
colleagu
found
statin
use
associ
reduc
pneumonia
risk
certain
dmassoci
infect
known
aggress
cours
poor
prognosi
especi
treat
promptli
exampl
includ
fournier
gangren
mucormycosi
dm
also
associ
increas
risk
death
infect
prospect
multicent
cohort
studi
invas
candidiasi
type
dm
independ
associ
increas
mortal
analysi
multicent
cohort
found
dm
associ
increas
mortal
risk
within
first
year
communityacquir
pneumonia
cap
pittet
colleagu
found
dm
significantli
associ
increas
mortal
septicemia
surgic
icu
patient
center
diseas
control
prevent
report
million
american
adult
copd
preval
increas
among
peopl
age
year
among
age
year
older
main
caus
hospit
copd
exacerb
cardiovascular
diseas
specif
infect
acut
exacerb
copd
even
therapi
patient
copd
acut
exacerb
averag
year
copd
exacerb
due
recurr
infect
viral
bacteri
pathogen
virus
may
account
exacerb
metaanalysi
studi
found
picornaviru
commonli
detect
viru
follow
influenza
respiratori
syncyti
viru
corona
virus
parainfluenza
viral
copd
exacerb
appear
sever
last
longer
without
viral
trigger
although
bacteria
frequent
colon
airway
copd
bacteri
exacerb
usual
associ
acquir
new
bacteri
strain
nontyp
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
pseudomona
aeruginosa
cap
copd
cours
frequent
complic
cap
cohort
studi
patient
copd
age
year
older
found
cap
incid
rate
per
personyear
populationbas
spanish
studi
cap
case
control
found
chronic
bronchiti
present
case
versu
control
independ
risk
factor
cap
use
inhal
corticosteroid
patient
copd
implic
increas
cap
risk
shown
metaanalysi
studi
combin
prepar
fluticasonesalmeterol
budesonideformoterol
cap
patient
copd
usual
present
sever
respiratori
failur
higher
pneumonia
sever
index
psi
pneumonia
common
isol
pathogen
follow
h
influenza
p
aeruginosa
aureu
catarrhali
atyp
pathogen
one
studi
found
copd
associ
increas
pneumococc
bacteremia
anoth
one
found
legionella
pneumophila
occur
predominantli
patient
without
copd
repeat
sever
copd
exacerb
risk
factor
cap
due
pseudomona
speci
copd
also
risk
factor
ventilatorassoci
pneumonia
vap
p
aeruginosa
acinetobact
speci
aureu
usual
caus
organ
system
corticosteroid
use
increas
risk
infect
multidrugresist
organ
patient
sever
copd
receiv
broadspectrum
antibiot
corticosteroid
increas
incid
invas
pulmonari
aspergillosi
ipa
guinea
colleagu
found
aspergillu
isol
lower
respiratori
tract
patient
per
copd
admiss
probabl
ipa
ipa
risk
factor
icu
admiss
receiv
antibiot
prior
month
accumul
corticosteroid
dose
mg
prior
month
studi
episod
sever
hospitalacquir
pneumonia
spanish
icu
found
episod
thought
due
aspergillu
speci
case
classifi
definit
patient
copd
steroid
one
prospect
studi
evalu
consecut
patient
sever
copd
moder
sever
persist
bronchial
asthma
bronchiectasi
admit
respiratori
icu
china
found
patient
ipa
cumul
prednison
dose
greater
mg
icu
admiss
independ
risk
factor
pneumocysti
jiroveci
caus
opportunist
fungal
respiratori
tract
infect
immunocompromis
patient
howev
frequent
colon
lung
detect
bronchoalveolar
lavag
immunocompet
patient
one
studi
patient
copd
increas
risk
pneumocysti
colon
infect
organ
consid
patient
copd
especi
corticosteroid
nonresolv
pneumonia
patient
copd
risk
influenza
infect
addit
copd
risk
factor
bacteri
coinfect
shown
influenza
pandem
spanish
hospit
manag
acut
copd
exacerb
includ
administr
antibiot
usual
presenc
increas
sputum
volum
purul
systemat
review
found
antibiot
significantli
reduc
treatment
failur
risk
although
evid
low
qualiti
infecti
diseas
societi
americaamerican
thorac
societi
outlin
evidencebas
clinic
practic
guidelin
cap
manag
stratifi
base
pneumonia
sever
nonicu
inpati
respiratori
fluoroquinolon
blactam
plu
macrolid
recommend
icu
patient
blactam
cefotaxim
ceftriaxon
ampicillinsulbactam
plu
either
azithromycin
fluoroquinolon
recommend
pseudomona
risk
exist
antipneumococc
antipseudomon
blactam
piperacillintazobactam
cefepim
imipenem
meropenem
plu
either
ciprofloxacin
levofloxacin
aminoglycosid
recommend
mrsa
risk
exist
vancomycin
linezolid
ad
voriconazol
primari
ipa
treatment
random
trial
show
surviv
benefit
patient
ipa
receiv
voriconazol
compar
amphotericin
b
howev
enrol
patient
allogen
hematopoieticcel
transplant
acut
leukemia
hematolog
diseas
use
combin
therapi
remain
controversi
evid
support
combin
antifung
therapi
salvag
fail
monotherapi
influenza
usual
treat
neuraminidas
inhibitor
oseltamivir
zanamivir
sever
case
recommend
increas
oseltamivir
dosag
mg
mg
twice
daili
food
drug
administr
approv
use
peramivir
intraven
neuraminidas
inhibitor
treatment
patient
sever
influenza
system
corticosteroid
use
acut
copd
exacerb
role
manag
patient
copd
pneumonia
less
defin
hyperglycemia
may
develop
blood
glucos
control
may
need
evalu
adren
insuffici
corticosteroid
replac
consid
sever
copd
frequent
exacerb
corticosteroid
use
emerg
literatur
effect
cardioprotect
medic
hospit
patient
copd
exacerb
includ
infect
patient
copd
increas
risk
specif
cardiovascular
condit
arrhythmia
angina
acut
myocardi
infarct
hf
stroke
pulmonari
embol
one
retrospect
studi
patient
hospit
copd
exacerb
found
bblocker
use
associ
reduc
mortal
nest
casecontrol
studi
found
year
statin
use
associ
reduct
mortal
risk
copd
retrospect
cohort
studi
elderli
patient
hospit
copd
exacerb
current
statin
use
angiotensinconvert
enzym
inhibitorangiotensin
receptor
blocker
use
significantli
associ
decreas
mortal
outcom
infect
patient
copd
usual
associ
signific
morbid
mortal
acut
copd
exacerb
requir
hospit
associ
allcaus
mortal
mortal
predictor
includ
higher
valu
acut
physiolog
score
system
low
glasgow
coma
scale
icu
admiss
cardiac
dysrhythmia
length
hospit
stay
icu
admiss
relationship
mortal
copd
cap
inconsist
one
studi
show
increas
mortal
risk
one
find
higher
mortal
studi
found
increas
mortal
hospit
patient
copd
cap
gener
mortal
ascrib
cap
popul
one
prospect
observ
studi
patient
vap
found
copd
independ
predictor
icu
mortal
anoth
studi
mechan
ventil
patient
copd
found
vap
independ
associ
icu
mortal
mortal
associ
ipa
patient
copd
extrem
high
reach
ckd
global
public
health
problem
unit
state
noninstitution
adult
estim
ckd
predict
patient
incid
endstag
renal
diseas
esrd
per
year
preval
patient
unit
state
patient
ckd
high
sepsi
preval
sever
evalu
esrd
program
unit
state
found
new
patient
hemodialysi
infectionrel
hospit
within
first
year
increas
almost
especi
first
month
studi
patient
hemodialysi
found
episod
bacteri
fungal
infect
infect
rate
episod
per
dialysisday
dialysisrel
infect
respons
episod
follow
belowthekne
ssti
pneumonia
ssti
infect
acquir
commun
almost
half
cultur
organ
gramposit
cocci
aerob
gramneg
bacilli
fifti
percent
total
infect
episod
occur
final
year
life
central
venou
cathet
frequent
vascular
access
dialysi
initi
among
patient
incid
esrd
incid
catheterrel
blood
stream
infect
crbsi
rang
episod
per
catheterday
crbsi
diagnosi
usual
confirm
isol
microorgan
quantit
cultur
cathet
peripher
blood
septic
patient
without
appar
sourc
crbsicaus
agent
gramposit
organ
commonli
aureu
staphylococcu
epidermidi
periton
periton
complic
periton
dialysi
pd
one
australian
studi
show
periton
rate
episod
per
patientyear
gramposit
organ
common
caus
organ
follow
gramneg
bacteria
cultur
polymicrobi
may
neg
evalu
patient
incid
pd
identifi
requir
icu
admiss
found
sepsi
second
common
reason
icu
admiss
cardiac
problem
periton
account
sepsi
admiss
patient
ckd
usual
sever
cap
reflect
higher
psi
compar
patient
microbiolog
similar
nonckd
pneumonia
frequent
pathogen
empir
antimicrobi
therapi
crbsi
includ
broadspectrum
coverag
gramposit
gramneg
organ
owe
high
mrsa
preval
hemodialysi
set
empir
therapi
includ
antimrsa
coverag
deescal
cultur
result
becom
avail
antimicrobi
therapi
usual
administ
day
durat
extend
week
persist
bacteremia
fungemia
occur
hour
hemodialysi
cathet
remov
patient
endocard
suppur
thrombophleb
week
treatment
osteomyel
use
antibiot
cathet
lock
suggest
institut
cathet
salvag
desir
absenc
exit
site
tunnel
infect
manag
periton
associ
pd
systemat
review
found
similar
primari
respons
relaps
rate
intraperiton
glycopeptidebas
regimen
compar
firstgener
cephalosporin
regimen
nevertheless
glycopeptidebas
regimen
like
achiev
complet
cure
review
also
found
intraperiton
medic
immunocompromis
patient
antibiot
superior
intraven
antibiot
reduc
treatment
failur
base
one
studi
patient
tunnel
infect
port
abscess
requir
remov
cathet
incis
drainag
indic
crbsi
associ
tunnel
hemodialysi
access
cathet
surgic
remov
follow
condit
present
sever
complic
sever
sepsi
endocard
suppur
thrombophleb
persist
bacteremia
persist
clinic
infect
sign
despit
hour
appropri
antimicrobi
therapi
infect
aureu
p
aeruginosa
multidrugresist
organ
fungi
mycobacetria
patient
pd
surgic
remov
pd
cathet
perform
presenc
refractori
periton
defin
failur
effluent
clear
day
appropri
antibiot
earli
arterioven
fistula
plan
institut
may
reduc
accessrel
infect
metaanalysi
trial
found
antibiot
cathet
lock
solut
significantli
reduc
crbsi
cathet
remov
clinic
practic
guidelin
recommend
prophylact
use
antimicrobi
lock
solut
patient
longterm
cathet
histori
multipl
crbsi
despit
optim
maxim
adher
asept
techniqu
cardiovascular
medic
patient
ckd
studi
relationship
sepsi
prospect
multicent
cohort
studi
incid
dialysi
patient
followup
found
sepsisrel
hospit
less
frequent
patient
receiv
statin
receiv
statin
outcom
populationbas
studi
unit
state
found
infect
account
esrd
death
second
cardiovascular
diseas
sepsisrel
mortal
esrd
approxim
higher
compar
gener
popul
systemat
review
studi
compris
icu
admiss
cardiovascular
diseas
sepsi
account
admiss
hospit
mortal
patient
esrd
high
compar
match
patient
mild
acut
kidney
injuri
studi
patient
esrd
admit
canadian
icu
mostli
sepsi
mortal
icu
month
followup
among
patient
ckd
cap
mortal
rate
markedli
higher
dialysi
patient
compar
gener
popul
prior
pneumococc
vaccin
associ
reduc
mortal
risk
retrospect
studi
pd
patient
infecti
periton
mortal
rate
periton
directli
implic
death
infecti
death
anoth
studi
critic
ill
pd
patient
sepsi
due
periton
common
admit
diagnosi
found
mortal
unit
state
approxim
popul
chronic
liver
diseas
cirrhosi
major
caus
death
worldwid
lifethreaten
infect
major
reason
admiss
hospit
icu
cirrhosisrel
infect
uniqu
term
present
outcom
therapeut
option
patient
cirrhosi
may
differ
present
infect
compar
patient
studi
shown
onethird
patient
cirrhosi
fail
develop
leukocytosi
temperatur
higher
c
lower
c
patient
cirrhosi
lower
baselin
blood
pressur
higher
heart
rate
respiratori
rate
therefor
complet
workup
includ
diagnost
paracentesi
ascit
fluid
cultur
urin
blood
cultur
chest
radiograph
done
soon
sepsi
suspect
sbp
frequent
infect
cirrhosi
account
document
bacteri
infect
hospit
patient
cirrhosi
european
associ
studi
liver
easl
recommend
sbp
diagnosi
base
neutrophil
count
ascit
fluid
higher
easl
defin
bacterascit
ascit
neutrophil
count
lower
posit
ascit
fluid
cultur
recommend
antimicrobi
therapi
patient
exhibit
sign
system
inflamm
infect
frequent
isol
organ
sbp
e
coli
klebsiella
speci
enterobacteriacea
microbiolog
etiolog
sbp
chang
recent
year
particular
upsurg
isol
quinoloneresist
gramneg
bacteria
extendedspectrum
blactamas
multidrugresist
gramposit
bacteria
recent
studi
shown
increas
enterococcu
speci
aureu
candida
speci
attribut
nosocomi
infect
recent
antibiot
treatment
cap
bacteri
cap
common
patient
cirrhosi
fact
cirrhosi
minor
criterion
defin
sever
cap
compar
patient
patient
cirrhosi
frequent
present
impair
conscious
septic
shock
higher
psi
score
class
ivv
bacteremia
pneumonia
common
microorgan
follow
h
influenza
l
pneumophila
ssti
constitut
approxim
infect
patient
cirrhosi
infect
caus
gramposit
aureu
group
streptococci
gramneg
bacteria
klebsiella
speci
aeromona
speci
vibrio
vulnificu
cellul
frequent
observ
ssti
necrot
fasciiti
less
common
predominantli
caus
gramneg
bacilli
necrot
fasciiti
v
vulnificu
attribut
contamin
shellfish
report
patient
cirrhosi
communityacquir
bacteri
mening
patient
cirrhosi
uncommon
seriou
infect
danish
cohort
studi
patient
cirrhosi
bacteri
mening
incid
per
personyear
highest
alcohol
cirrhosi
per
personyear
unfortun
diagnosi
often
delay
su
colleagu
show
among
mening
case
patient
cirrhosi
mening
initi
tent
diagnosi
patient
wherea
given
altern
diagnos
hepat
encephalopathi
seizur
alcohol
withdraw
contrast
patient
without
cirrhosi
label
altern
diagnos
patient
cirrhosi
mening
present
lower
glasgow
coma
scale
like
seizur
septic
shock
sign
mening
irrit
may
delay
absent
mental
statu
chang
often
confus
hepat
encephalopathi
data
microbiolog
base
small
seri
show
distinct
pathogen
su
colleagu
show
k
pneumonia
respons
case
case
caus
salmonella
listeria
monocytogen
p
aeruginosa
anoth
seri
case
e
coli
l
monocytogen
statist
common
patient
cirrhosi
without
cirrhosi
endotips
endotips
refer
transjugular
intrahepat
portosystem
shunt
tip
infect
definit
still
debat
involv
persist
bacteremia
fever
togeth
either
shunt
occlus
veget
bacteremia
presenc
patent
shunt
sourc
bacteremia
rule
base
small
case
seri
endotips
incid
approxim
rang
patient
present
fever
chill
bacteremia
either
occur
earli
day
late
day
stent
insert
caus
organ
enterobacteriacea
speci
enterococcu
speci
staphylococcu
speci
streptococcu
speci
anaerob
speci
lactobacillu
speci
fungal
organ
organ
empir
antibiot
start
immedi
follow
diagnosi
sbp
common
caus
organ
sbp
gramneg
aerob
bacteria
easl
recommend
thirdgener
cephalosporin
firstlin
antibiot
treatment
amoxicillinclavulan
acid
quinolon
altern
option
howev
quinolon
recommend
use
sbp
prophylaxi
area
high
preval
quinoloneresist
nosocomi
sbp
nosocomi
sbp
incid
esblproduc
bacteria
well
multidrugresist
gramposit
bacteria
enterococcu
faecium
mrsa
increas
empir
therapi
carbapenem
glycopeptid
suggest
nosocomi
infect
high
suspicion
multidrugresist
organ
deescal
soon
possibl
manag
cap
patient
cirrhosi
follow
guidelin
outlin
previous
copd
section
clinic
practic
guidelin
infecti
diseas
societi
america
european
feder
neurolog
societi
specif
address
bacteri
mening
patient
cirrhosi
given
uniqu
microbiolog
popul
import
empir
antimicrobi
therapi
cover
k
pneumonia
e
coli
listeria
monocytogen
pneumococcu
ssti
treat
broadspectrum
antimicrobi
time
surgic
intervent
necrot
fasciiti
treatment
endotips
reli
mainli
antimicrobi
therapi
infect
stent
remov
impract
broadspectrum
antibiot
cover
gramposit
gramneg
bacteria
initi
vancomycin
plu
thirdgener
cephalosporin
common
regimen
report
seri
carbapenem
may
use
increas
risk
multidrugresist
organ
fungal
infect
suspect
antifung
therapi
start
patient
cirrhosi
present
septic
shock
recent
multin
cohort
studi
reveal
use
inappropri
initi
antimicrobi
relat
increas
mortal
addit
singl
rather
appropri
antimicrobi
also
associ
higher
mortal
support
therapi
random
control
studi
sbp
patient
treat
cefotaxim
show
albumin
significantli
reduc
mortal
compar
cefotaxim
alon
await
evid
easl
recommend
patient
develop
sbp
treat
broadspectrum
antibiot
intraven
albumin
rel
adren
insuffici
common
patient
cirrhosi
septic
shock
random
control
trial
patient
cirrhosi
present
septic
shock
hydrocortison
therapi
result
signific
hemodynam
improv
compar
placebo
howev
mortal
benefit
hydrocortison
therapi
associ
increas
shock
relaps
gastrointestin
bleed
recent
random
control
trial
compar
mgkg
granulocyt
colonystimul
factor
gcsf
placebo
patient
acuteonchron
liver
failur
found
signific
improv
surviv
day
vs
reduct
sepsi
incid
howev
recent
metaanalysi
use
gcsf
patient
sever
sepsi
septic
shock
show
benefit
whether
gcsf
special
benefit
patient
cirrhosi
remain
unknown
infect
patient
cirrhosi
gener
carri
poor
prognosi
inhospit
mortal
first
episod
sbp
rang
mortal
report
similarli
cap
cirrhosi
associ
mortal
factor
associ
mortal
includ
impair
conscious
multilobar
pneumonia
ascit
acut
renal
failur
bacteremia
icu
admiss
high
model
endstag
liver
diseas
score
mening
report
mortal
patient
cirrhosi
patient
cirrhosi
develop
septic
shock
mortal
reach
research
import
group
patient
need
special
focu
systembas
intervent
improv
deliveri
time
appropri
manag
estim
million
peopl
hf
worldwid
includ
million
peopl
unit
state
alon
patient
hf
increas
risk
cap
common
reason
hospit
addit
hf
risk
factor
admiss
patient
cap
icu
patient
hf
increas
risk
influenza
infect
includ
document
influenza
infect
diagnost
approach
patient
sever
cap
outlin
earlier
copd
section
viral
pneumonia
suspect
respiratori
sampl
viral
pathogen
includ
polymeras
chain
reaction
pcr
obtain
cap
diagnosi
acut
hf
may
difficult
similar
condit
physic
medic
immunocompromis
patient
examin
chest
radiographi
serum
btype
natriuret
peptid
ntermin
probtyp
natriuret
peptid
may
help
differenti
entiti
patient
present
acut
dyspnea
recent
trial
patient
present
emerg
depart
dyspnea
found
model
use
procalcitonin
accur
individu
clinic
variabl
pneumonia
diagnosi
patient
acut
hf
studi
found
patient
acut
hf
elev
procalcitonin
concentr
ngml
wors
outcom
treat
antibiot
thorac
ultrasound
demonstr
bline
suggest
thicken
interstiti
fluidfil
alveoli
seen
commonli
patient
hf
suggest
aid
differenti
pneumonia
hf
manag
cap
patient
hf
follow
infecti
diseas
societi
americaamerican
thorac
societi
consensu
guidelin
summar
copd
section
patient
suspect
sever
influenza
includ
treat
oseltamivir
soon
possibl
populationbas
cohort
studi
adult
patient
hospit
pneumonia
found
mortal
among
patient
hf
compar
among
patient
sever
hf
substanti
increas
mortal
similarli
hf
independ
associ
increas
mortal
risk
patient
infect
physician
care
patient
lifethreaten
infect
know
associ
chronic
ill
ill
may
affect
immun
function
predispos
patient
specif
infect
could
caus
multidrugresist
opportunist
organ
knowledg
crucial
proper
care
manag
addit
prospect
studi
manag
lifethreaten
infect
patient
dm
copd
hf
ckd
cirrhosi
need
understand
special
characterist
specif
diagnost
therapeut
approach
